Contamination, Dermatology and Development - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Contamination

Dermatology

Development

Ycanth (Cantharidin) Revolutionizes Molluscum Contagiosum Treatment with FDA Approval

XTalks

AUGUST 7, 2023

Ycanth (cantharidin) topical solution, developed by Verrica Pharmaceuticals Inc., Verrica, a company specializing in dermatology therapeutics, has designed Ycanth to be delivered through a single-use applicator. This condition is marked by the appearance of small, raised lesions known as mollusca, which usually develop on the body.

FDA Approval

FDA Approval Dermatology Trials Clinical Trials

Topical products: Aiming for quality, simplicity, and cost-efficiency in their development, scale-up, and manufacturing

Pharmaceutical Technology

JANUARY 6, 2023

The preparation of a semi-solid dosage form – from formulation and development, to scale-up, commercial manufacturing, and packaging – should ideally take place under one roof in a contiguous, end-to-end workflow to avoid unnecessary equipment and process changes. Optimising development and scale-up. Particle distribution. Grittiness.

Production

Production Manufacturing Development Bioequivalency

Ycanth (Cantharidin) Revolutionizes Molluscum Contagiosum Treatment with FDA Approval

Topical products: Aiming for quality, simplicity, and cost-efficiency in their development, scale-up, and manufacturing

Stay Connected